CABAZITAXEL DR.REDDY'S cabazitaxel 60 mg/1.5 mL concentrated injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

cabazitaxel, Quantity: 60 mg

Verfügbar ab:

Dr Reddys Laboratories Australia Pty Ltd

Darreichungsform:

Injection, concentrated

Zusammensetzung:

Excipient Ingredients: polysorbate 80; citric acid

Verabreichungsweg:

Intravenous Infusion

Einheiten im Paket:

1

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Cabazitaxel Dr.Reddy?s in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

Produktbesonderheiten:

Visual Identification: Clear yellow to brownish-yellow viscous solution.; Container Type: Multiple containers; Container Material: Glass; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2018-07-23